Connecting with the Global Pharma Industry at Taiwan Bio Expo 2026

On July 16–19, 2026 – SMS showcased its starch-based pharmaceutical excipients, DAVAMED™ Series and TAPIOPHARM™ Series, at Taiwan Bio Expo 2026, held at the Taipei Nangang Exhibition Center (TaiNEX 1 & 2).

Recognized as Taiwan's largest biotechnology, life sciences, and pharmaceutical exhibition—and one of Asia's leading bio industry events—Taiwan Bio Expo brings together global innovators, researchers, manufacturers, investors, and healthcare professionals to explore the latest advances shaping the future of healthcare and biotechnology.

At this year's exhibition, SMS is showcasing its expertise in starch-based pharmaceutical excipients through its DAVAMED™ and TAPIOPHARM™ product portfolios. Manufactured from premium tapioca and corn starch under stringent quality standards, the company's excipient solutions—including the EXCiPACT-certified DAVAMED™ Series—are designed to provide pharmaceutical and nutraceutical manufacturers with reliable functionality, consistent performance, and dependable quality across a wide range of dosage formulations. 

By participating in Taiwan Bio Expo 2026, SMS continues to strengthen its presence in the global pharmaceutical market while connecting with industry partners to drive innovation and support the development of high-quality healthcare solutions worldwide.